Incyte(INCY.US)

Last Updated 19:00:00 ET
longbridge loading

Incyte Stock: Analyst Estimates & Ratings

Barchart Option·
US
INCY
+0.43%
US
LABD
+2.41%
US
IHE
+1.26%
Barchart Option·
US
INCY
+0.43%
US
LABD
+2.41%
US
IHE
+1.26%

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Market Beat·
US
INCY
+0.43%
US
PBE
+0.11%
US
IBB
+0.10%
Market Beat·
US
INCY
+0.43%
US
PBE
+0.11%
US
IBB
+0.10%

Incyte Corp. Stock Underperforms Friday When Compared To Competitors

MarketWatch Automated·
US
INCY
+0.43%
MarketWatch Automated·
US
INCY
+0.43%

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

MarketWatch Automated·
US
INCY
+0.43%
US
PBE
+0.11%
US
LABU
-2.35%
MarketWatch Automated·
US
INCY
+0.43%
US
PBE
+0.11%
US
LABU
-2.35%

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

MarketWatch Automated·
US
INCY
+0.43%
US
ARKG
+0.04%
US
BBH
+0.68%
MarketWatch Automated·
US
INCY
+0.43%
US
ARKG
+0.04%
US
BBH
+0.68%

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

TradingView·
US
PRLD
-1.61%
US
INCY
+0.43%
TradingView·
US
PRLD
-1.61%
US
INCY
+0.43%

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress | INCY Stock News

StockTitan·
US
INCY
+0.43%
US
VHT
+0.97%
US
FBT
+0.54%
StockTitan·
US
INCY
+0.43%
US
VHT
+0.97%
US
FBT
+0.54%

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

MarketWatch Automated·
US
INCY
+0.43%
US
BBH
+0.68%
US
VHT
+0.97%
MarketWatch Automated·
US
INCY
+0.43%
US
BBH
+0.68%
US
VHT
+0.97%

Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

Tip Ranks·
US
INCY
+0.43%
US
XBI
-0.69%
US
IHE
+1.26%
Tip Ranks·
US
INCY
+0.43%
US
XBI
-0.69%
US
IHE
+1.26%
© 2026 Longbridge｜Disclaimer